Page last updated: 2024-08-24

irinotecan and pp242

irinotecan has been researched along with pp242 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Atreya, CE; Bergsland, EK; Ducker, GS; Feldman, ME; Shokat, KM; Warren, RS1
Corbacioglu, S; Heise, T; Leister, J; Matthes, M; Penkivech, G; Sommer, G; Waetzig, R1

Other Studies

2 other study(ies) available for irinotecan and pp242

ArticleYear
Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
    Investigational new drugs, 2012, Volume: 30, Issue:6

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Indoles; Irinotecan; Mutation; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Purines; ras Proteins; TOR Serine-Threonine Kinases; Transcription Factors

2012
Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells.
    International journal of medical sciences, 2021, Volume: 18, Issue:1

    Topics: Administration, Metronomic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Indoles; Inhibitory Concentration 50; Irinotecan; Naphthyridines; Neuroblastoma; Purines; Pyrimidines; Signal Transduction; Sirolimus; Temozolomide; Thiourea; TOR Serine-Threonine Kinases

2021